<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01305551</url>
  </required_header>
  <id_info>
    <org_study_id>CV181-146</org_study_id>
    <nct_id>NCT01305551</nct_id>
  </id_info>
  <brief_title>BE Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin HCl XR Tablet Relative to a 5 mg Saxagliptin (Onglyza™) Tablet and a 500 mg Metformin HCl XR (Glifage® XR Marketed in Brazil by Merck S.A.) Tablet Co-Administered to Healthy Subjects in the Fasted and Fed States</brief_title>
  <official_title>Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin Hydrochloride (HCl) XR Tablet Relative to a 5 mg Saxagliptin (Onglyza™) Tablet and a 500 mg Metformin HCl XR (Glifage® XR Marketed in Brazil by Merck S.A.) Tablet Co-Administered to Healthy Subjects in the Fasted and Fed States</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the bioequivalence (BE) of Saxagliptin and
      Metformin from a 5 mg Saxagliptin/500 mg Metformin extended release (XR) fixed dose
      combination (FDC) tablet relative to 5 mg Onglyza™ and 500 mg Glifage® XR (marketed in Brazil
      by Merck S.A.) tablets administered together in both the fasted and fed states.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary purpose: To demonstrate the bioequivalence of Saxagliptin and Metformin from a 5 mg
      Saxagliptin/500 mg Metformin XR FDC tablet relative to 5 mg Onglyza™ and 500 mg Glifage® XR
      (marketed in Brazil by Merck S.A.) tablets administered together in both the fasted and fed
      states.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evidence of BE on single-dose pharmacokinetic parameters maximum observed concentration (Cmax) derived from Saxagliptin, 5-Hydroxy Saxagliptin and Metformin plasma concentration versus time data.</measure>
    <time_frame>48 hours after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evidence of BE on single-dose pharmacokinetic parameters time of maximum observed concentration (Tmax) derived from Saxagliptin, 5-Hydroxy Saxagliptin and Metformin plasma concentration versus time data.</measure>
    <time_frame>48 hours after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evidence of BE on single-dose pharmacokinetic parameters (AUC(0-T) derived from Saxagliptin, 5-Hydroxy Saxagliptin and Metformin plasma concentration versus time data.</measure>
    <time_frame>48 hours after dosing</time_frame>
    <description>Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUC(0-T))</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evidence of BE on single-dose pharmacokinetic parameters area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) derived from Saxagliptin, 5-Hydroxy Saxagliptin and Metformin plasma concentration versus time data.</measure>
    <time_frame>48 hours after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evidence of BE on single-dose pharmacokinetic parameters half-life (T-HALF) derived from Saxagliptin, 5-Hydroxy Saxagliptin and Metformin plasma concentration versus time data.</measure>
    <time_frame>48 hours after dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>3 days after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Active metabolite of Saxagliptin, 5-Hydroxy Saxagliptin, from 5 mg Saxagliptin/500 mg Metformin XR FDC tablet &amp; from 5 mg Onglyza administered together with 500 mg Glifage® XR in single-dose fed &amp; fasted state pharmacokinetics in healthy subjects</measure>
    <time_frame>3 days after dosing</time_frame>
    <description>Amount of the active metabolite of Saxagliptin, 5-Hydroxy Saxagliptin (BMS-510849), from the 5 mg Saxagliptin/500 mg Metformin XR FDC tablet and from 5 mg Onglyza™ administered together with 500 mg Glifage® XR (marketed in Brazil by Merck S.A.) in single-dose fed and fasted state pharmacokinetics in healthy subjects</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Treatment A-Saxagliptin+Metformin XR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5mg Saxagliptin + 500 mg Metformin XR Tablets, once on Day 1 only, administered together in the fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B-Saxagliptin/Metformin XR FDC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5mg Saxagliptin / 500 mg Metformin XR FDC tablet, once on Day 1 only, administered in the fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C-Saxagliptin+Metformin XR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5mg Saxagliptin + 500 mg Metformin XR Tablets, once on Day 1 only, administered together in the fed state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D-Saxagliptin/Metformin XR FDC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5mg Saxagliptin / 500 mg Metformin XR FDC tablet, once on Day 1 only, administered in the fed state.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saxagliptin</intervention_name>
    <description>Tablet, Oral, 5 mg, once on Day 1 only</description>
    <arm_group_label>Treatment A-Saxagliptin+Metformin XR</arm_group_label>
    <arm_group_label>Treatment C-Saxagliptin+Metformin XR</arm_group_label>
    <other_name>Onglyza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin XR</intervention_name>
    <description>Tablet, Oral, 500 mg, once on Day 1 only</description>
    <arm_group_label>Treatment A-Saxagliptin+Metformin XR</arm_group_label>
    <arm_group_label>Treatment C-Saxagliptin+Metformin XR</arm_group_label>
    <other_name>Glifage XR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saxagliptin/Metformin XR FDC</intervention_name>
    <description>Tablet, Oral, 5/500 mg, once on Day 1 only</description>
    <arm_group_label>Treatment B-Saxagliptin/Metformin XR FDC</arm_group_label>
    <arm_group_label>Treatment D-Saxagliptin/Metformin XR FDC</arm_group_label>
    <other_name>Onglyza/Glucophage</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy men and women

          -  Women of childbearing potential (WOCBP) who are using acceptable method of
             contraception

          -  Women who are not nursing

        Exclusion Criteria:

          -  History of Gastrointestinal (GI) disease

          -  Any GI surgery that could impact study drug absorption

          -  History of allergy to drug class or related compounds

          -  History of allergy to metformin or other similar acting agents.

          -  History of any significant drug allergy.

          -  Estimated creatinine clearance (ClCr) &lt; 80 mL/min using Cockcroft-Gault formula
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Campinas</city>
        <state>Sao Paulo</state>
        <zip>13073</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2011</study_first_submitted>
  <study_first_submitted_qc>February 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2011</study_first_posted>
  <last_update_submitted>June 4, 2014</last_update_submitted>
  <last_update_submitted_qc>June 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 5, 2014</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>Bristol-Myers Squibb</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Saxagliptin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

